In the news
Developing Next generation Liquid Embolics
Instylla is a privately held company based in Bedford, MA, focused on developing next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis.
The company’s first product, Embrace™ Hydrogel Embolic System, is designed for controlled, complete, and persistent embolization in these clinical conditions.
Instylla Initiates Commercial Launch with First Use of the Embrace™ Hydrogel Embolic System
Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial
Instylla Gains U.S. FDA Premarket Approval for Embrace™ Hydrogel Embolic System
First and Only Liquid Embolic Approved for Hypervascular Tumor Embolization Supported by a Prospective, Randomized, Controlled, Clinical Trial BEDFORD, Mass., August 7, 2025 – Instylla, Inc.,
Instylla Appoints MedTech Leader Sean Boyle as Chief Executive Officer
BEDFORD, Mass., Aug 5, 2025 – Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolization, has announced the appointment of Sean Boyle
Instylla Announces the Appointment of Daniel Davis to Board of Directors
BEDFORD, Mass., – Apr 15, 2025 – Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolization, has announced the appointment of Daniel
Instylla Completes Submission of Premarket Approval Application for Embrace™ Hydrogel Embolic System
BEDFORD, Mass., – March 11, 2025 – Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval application (PMA) for the Embrace™ Hydrogel Embolic System (HES).
Instylla Announces FDA Clearance of Tembo™ Embolic System
BEDFORD, Mass., – Jan 28, 2025 – Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System. The Tembo Embolic System is a bioresorbable1 embolization agent comprised of irregularly shaped, dry gelatin particles of a size range from 85-255µm1…
Instylla: An Easy, Predictable, and Simpler Way to Embolize Tumors
Liquid Embolics: Emerging Options and Applications
Flowing on the horizon: Liquid embolics in development
In addition to meeting both primary safety and effectiveness endpoints, the Instylla HES Hypervascular Tumor Study reported several key additional observations.
#EmbraceHES #InterventionalRadiology #Embolization
We’re looking forward to being at the Interventional Radiology IEP Residents' & Young Physicians' Conference in Austin this weekend.
Visit us at Booth #4 to connect with our team and learn more about Embrace® HES
#InterventionalRadiology #InterventionalOncology #EmbraceHES
Natalie Costello gets a front-row seat to something special: meeting every candidate who walks through Instylla's doors alongside Lindsay Streett, and playing a direct role in shaping our talent and culture. Hear more from Natalie⬇️⬇️
Embrace the Case. 69M, advanced HCC, prior systemic and locoregional therapy, extrahepatic disease present. Complete Response per mRECIST at 30 and 90 days. No progression. No revascularization.
https://instylla.com/case-studies/transarterial-embolization-for-advanced-hcc-in-a-69-year-old-male-with-prior-therapies/
#EmbraceHES #HCC #IR
